Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quotient Clinical will take up rapid formulation development and clinical testing (RapidFACT) program to optimize nasal delivery of Phico Therapeutics' SASPject PT1.2
Subscribe to our email newsletter
SASPject PT1.2 is an antibiotic protein technology that offers a new approach to treat serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).
RapidFACT will be used to screen alternative formulations designed to enhance nasal delivery, retention and efficacy of SASPject in intranasal S. aureus carriers.
Quotient MD Mark Egerton said they are looking forward to delivering an optimized drug product for the next stages of development, and helping Phico to accelerate its novel approach into patient studies.